Deutsche Bank AG Acquires 37,686 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Deutsche Bank AG lifted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 258,964 shares of the biotechnology company's stock after purchasing an additional 37,686 shares during the quarter. Deutsche Bank AG owned approximately 0.21% of Arrowhead Pharmaceuticals worth $4,869,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. R Squared Ltd acquired a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $38,000. Van ECK Associates Corp grew its stake in Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after buying an additional 1,250 shares during the last quarter. KBC Group NV grew its stake in Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after buying an additional 1,644 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at $190,000. Finally, First Citizens Bank & Trust Co. acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at $205,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ARWR. Chardan Capital reiterated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. B. Riley reiterated a "buy" rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Citigroup lowered their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $42.13.

Insider Activity at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the company's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $11.49, for a total value of $583,692.00. Following the sale, the chief executive officer now owns 3,921,255 shares of the company's stock, valued at $45,055,219.95. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 275,880 shares of company stock valued at $4,034,037 over the last quarter. 4.30% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock traded up $0.08 during mid-day trading on Thursday, reaching $15.39. The company had a trading volume of 1,473,852 shares, compared to its average volume of 1,496,765. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $30.41. The company has a 50 day moving average of $13.33 and a 200-day moving average of $17.73. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -2.98 and a beta of 0.89.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to the consensus estimate of $116.27 million. During the same period last year, the company earned ($1.02) earnings per share. On average, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.